How to Decrease Systemic Corticosteroids in Pemphigus Patients Under Rituximab

Overview

Journal Health Sci Rep

Specialty General Medicine

Date 2022 Jun 9

PMID 35677471

Authors

Fabrizio Martora

Vincenzo Picone

Gabriella Fabbrocini

Matteo Megna

Affiliations

Soon will be listed here.

References

Ruggiero A, Fabbrocini G, Cinelli E, Megna M . Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison. J Am Acad Dermatol. 2021; 85(4):1028-1030. DOI: 10.1016/j.jaad.2021.01.025. View

Nili A, Tavakolpour S, Mahmoudi H, Noormohammadpour P, Balighi K, Daneshpazhooh M . Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases. Immunopharmacol Immunotoxicol. 2020; 42(1):56-58. DOI: 10.1080/08923973.2020.1717526. View

Feldman R . Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol. 2015; 173(3):858-9. DOI: 10.1111/bjd.13823. View

Porro A, Arai Seque C, Ferreira M, Enokihara M . Pemphigus vulgaris. An Bras Dermatol. 2019; 94(3):264-278. PMC: 6668932. DOI: 10.1590/abd1806-4841.20199011. View

Mignard C, Maho-Vaillant M, Golinski M, Balaye P, Prost-Squarcioni C, Houivet E . Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Dermatol. 2020; 156(5):545-552. PMC: 7081151. DOI: 10.1001/jamadermatol.2020.0290. View

Frampton J . Rituximab: A Review in Pemphigus Vulgaris. Am J Clin Dermatol. 2019; 21(1):149-156. DOI: 10.1007/s40257-019-00497-9. View

Di Lernia V, Casanova D, Goldust M, Ricci C . Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. Dermatol Pract Concept. 2020; 10(3):e2020050. PMC: 7319750. DOI: 10.5826/dpc.1003a50. View

Mahmoudi H, Tavakolpour S, Balighi K, Salehi Farid A, Nili A, Jan D . Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther. 2020; 34(1):e14633. DOI: 10.1111/dth.14633. View

Martora F, Martora L, Fabbrocini G, Marasca C . A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa?. Skin Appendage Disord. 2022; 8(3):265-268. PMC: 9149405. DOI: 10.1159/000521712. View

10.

Daneshpazhooh M, Balighi K, Mahmoudi H, Tavakolpour S, Abedini R, Soori T . Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019; 32(5):e13016. DOI: 10.1111/dth.13016. View

11.

Marano L, Fabbrocini G, Monfrecola G, Martora F . An Unusual Case of Pemphigus Vulgaris. Skin Appendage Disord. 2022; 8(2):158-160. PMC: 8928182. DOI: 10.1159/000521333. View

12.

Joly P, Horvath B, Patsatsi A, Uzun S, Bech R, Beissert S . Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020; 34(9):1900-1913. DOI: 10.1111/jdv.16752. View

13.

Wang H, Liu C, Li Y, Huang Y . Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015; 95(8):928-32. DOI: 10.2340/00015555-2116. View

14.

Narayanan A, Ramam M, Bhari N . A retrospective case-control study of clinical factors associated with paradoxical exacerbation of pemphigus vulgaris following rituximab infusion. Int J Dermatol. 2020; 59(12):e459-e460. DOI: 10.1111/ijd.15127. View

15.

Mahmoudi H, Nili A, Salehi Farid A, Tavakolpour S, Daneshpazhooh M . Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption. Br J Dermatol. 2021; 185(1):e2. DOI: 10.1111/bjd.20054. View

16.

Kridin K, Ahmed A . The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review. Expert Opin Biol Ther. 2021; 21(4):443-454. DOI: 10.1080/14712598.2021.1874915. View